Eli Lilly And Co (NYSE:LLY) Shares Sold by Fiera Capital Corp

Fiera Capital Corp trimmed its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 44.4% in the 1st quarter, HoldingsChannel.com reports. The fund owned 14,838 shares of the company’s stock after selling 11,842 shares during the quarter. Fiera Capital Corp’s holdings in Eli Lilly And Co were worth $2,059,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of LLY. Norges Bank acquired a new position in shares of Eli Lilly And Co in the 4th quarter valued at $1,171,509,000. Jennison Associates LLC lifted its stake in shares of Eli Lilly And Co by 125.9% in the 1st quarter. Jennison Associates LLC now owns 10,192,052 shares of the company’s stock valued at $1,413,841,000 after purchasing an additional 5,679,574 shares during the period. BlackRock Inc. lifted its stake in shares of Eli Lilly And Co by 5.6% in the 1st quarter. BlackRock Inc. now owns 64,299,477 shares of the company’s stock valued at $8,919,623,000 after purchasing an additional 3,420,265 shares during the period. Capital International Investors lifted its stake in shares of Eli Lilly And Co by 3.6% in the 4th quarter. Capital International Investors now owns 26,055,933 shares of the company’s stock valued at $3,424,531,000 after purchasing an additional 910,672 shares during the period. Finally, FMR LLC lifted its stake in shares of Eli Lilly And Co by 6.7% in the 4th quarter. FMR LLC now owns 14,235,227 shares of the company’s stock valued at $1,870,935,000 after purchasing an additional 888,413 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Eli Lilly And Co stock opened at $151.16 on Friday. Eli Lilly And Co has a 52-week low of $101.36 and a 52-week high of $164.90. The firm has a market capitalization of $145.65 billion, a price-to-earnings ratio of 23.57, a PEG ratio of 1.82 and a beta of 0.25. The company has a fifty day simple moving average of $152.85 and a 200-day simple moving average of $136.00. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 4.37.

Eli Lilly And Co (NYSE:LLY) last released its earnings results on Thursday, April 23rd. The company reported $1.75 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.48 by $0.27. Eli Lilly And Co had a net margin of 23.97% and a return on equity of 194.18%. The business had revenue of $5.86 billion during the quarter, compared to analyst estimates of $5.48 billion. During the same quarter in the prior year, the firm earned $1.33 earnings per share. The company’s revenue for the quarter was up 15.1% compared to the same quarter last year. On average, research analysts anticipate that Eli Lilly And Co will post 6.81 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a $0.74 dividend. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.96%. The ex-dividend date is Thursday, May 14th. Eli Lilly And Co’s dividend payout ratio is currently 49.01%.

In related news, SVP Aarti S. Shah sold 2,000 shares of the company’s stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $150.00, for a total value of $300,000.00. Following the completion of the sale, the senior vice president now owns 19,087 shares of the company’s stock, valued at $2,863,050. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Stephen F. Fry sold 14,657 shares of the company’s stock in a transaction dated Monday, March 30th. The shares were sold at an average price of $134.30, for a total transaction of $1,968,435.10. Following the completion of the sale, the senior vice president now directly owns 110,572 shares of the company’s stock, valued at approximately $14,849,819.60. The disclosure for this sale can be found here. Insiders sold 906,320 shares of company stock valued at $132,984,238 in the last three months. 0.09% of the stock is currently owned by insiders.

LLY has been the subject of several recent analyst reports. Cfra boosted their price target on shares of Eli Lilly And Co from $146.00 to $167.00 and gave the stock a “hold” rating in a report on Friday, April 24th. Cantor Fitzgerald boosted their price target on shares of Eli Lilly And Co from $156.00 to $185.00 and gave the stock an “overweight” rating in a report on Friday, April 24th. Goldman Sachs Group raised shares of Eli Lilly And Co from a “buy” rating to a “conviction-buy” rating and set a $168.00 price target for the company in a report on Wednesday, March 11th. Morgan Stanley lowered shares of Eli Lilly And Co from an “overweight” rating to an “equal weight” rating in a report on Sunday, April 19th. Finally, Cowen boosted their price target on shares of Eli Lilly And Co from $145.00 to $160.00 and gave the stock an “outperform” rating in a report on Wednesday, April 15th. Four equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Eli Lilly And Co has an average rating of “Buy” and a consensus price target of $158.64.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: Discount Rate

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.